

(Registration No. 201101002327(930464-M)) (Incorporated in Malaysia)

NOTICE OF THIRTEENTH ANNUAL GENERAL MEETING							
NOTICE IS HEREBY GIVEN THAT the Thirteenth Annual General Meeting ("13 th AGM") of WCT Holdings Berhad ("WCT" or "the Company") NOTES:							
	e held virtually through live streaming from the broadcast venue at the Meeting Room, Level 3, Le Méridien Petaling J , Jalan SS7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor Darul Ehsan, Malaysia ("Broadcast Venue") on Thursday, 1:		A. 1.	VIRTUAL ANNUAL GENERAL MEETING The Company's 13 th AGM will be held as a fully virtual r	meeting where sharehold	ars are only allowed to pa	rticinate remotely via live
	a.m. for the following purposes:		1.	streaming and online voting using Remote Participation a	and Electronic Voting ("RP		
As O	AGENDA rdinary Business			boardroomlimited.my (Domain Registration No. with MYI Please follow the procedures provided in the Adu		r the 13 th AGM, which i	s available at this link
	To receive the Audited Financial Statements of the Company for the financial year ended 31 December 2023			https://www.wct.com.my/13thAGM/, in order to revia the RPEV facilities.			
2.	together with the Reports of the Directors and Auditors thereon. To re-elect the following Directors who retire in accordance with Article 82 of the Company's Constitution and		2.	Shareholders who have duly registered online to participa			
2.	being eligible, have offered themselves for re-election:			to participate (including to pose questions to the Comp use the query box facility to submit questions in real tin			
	 (a) Y. Bhg. Datuk Chow Ying Choon (b) Y. Bhq. Tan Sri Marzuki Bin Mohd Noor 	Resolution 1 Resolution 2	3.	meeting. The Broadcast Venue of the 13 th AGM is strictly for the pu	rnoso of complying with S	action 227(2) of the Comp	ppior Act 2016 ("the Act")
	(c) Puan Rahana Binti Abdul Rashid	Resolution 3	у.	which requires the Chairman of the meeting to be pres			
3.	To re-appoint Messrs Ernst & Young PLT as Auditors of the Company and to authorise the Directors to fix their remuneration.	Resolution 4	B.	physically present at the Broadcast Venue. PROXY			
As Special Business			1.	A member entitled to attend and vote at the meeting			end and vote using RPEV
To consider and, if thought fit, to pass the following Ordinary Resolutions:			2.	facilities, on his/her behalf and such proxy may but need In the case of a member who is an Exempt Authorised	Nominee as defined unde		Central Depositories) Act,
4.	Payment of Directors' fees "THAT the Directors' fees for the period from 14 June 2024 until the next Annual General Meeting ("AGM") of the		3.	1991, there is no limit as to the number of proxies it may If a member entitled to attend and vote at the meeting is		urticinate in the 13 th AGM v	ia the RPEV facilities such
	Company to be held in 2025, be and is hereby approved for payment."	Resolution 5	у.	member may appoint a proxy or the Chairman of the Me	eting as his/her proxy to p		
5.	Payment of Directors' benefits "THAT the Directors' benefits (excluding Directors' fees) for the period from 14 June 2024 until the next AGM of		4.	indicate his/her voting instructions in the instrument app Where a member appoints two (2) proxies or where an Ex		e appoints two (2) or more	proxies, the appointment
	the Company to be held in 2025, be and is hereby approved for payment."	Resolution 6		shall only be valid if the proportion of shareholdings to the proxies.	be represented by each pr	oxy is clearly specified in t	he instrument appointing
6.	Authority to Allot and Issue Shares pursuant to the Companies Act 2016 and Waiver of Pre-emptive Rights		5.	The instrument appointing a proxy shall be in writing un			
	"THAT, subject always to the Companies Act 2016 ("CA 2016"), the Constitution of the Company and the			or if the member is a corporation, shall be executed eith attorney duly authorised in writing.	er under its common seal	or under the hand of the	authorised officer or of its
	approvals of the relevant governmental/regulatory authorities (if any), the Directors of the Company be and are hereby empowered pursuant to Section 75 and 76 of the CA 2016, to allot and issue new shares in the		б.	The instrument appointing a proxy must either be Company, Boardroom Share Registrars Sdn Bhd at Grou			
	Company, at any time, at such price, upon such terms and conditions, for such purposes and to such person(s) whomsoever as the Directors may in their absolute discretion deem fit, provided that the aggregate number of			Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsa	in or submitted electroni	cally via the BoardRoom	Smart Investor Portal at
	shares issued pursuant to this approval does not exceed ten percent (10%) of the total number of issued shares			https://investor.boardroomlimited.com before 10.00 Administrative Details for further information on the subr	a.m. on 12 June 2024. mission of proxy form elect	tronically.	cedures provided in the
	of the Company for the time being AND THAT pursuant to Section 85 of the CA 2016 to be read together with Article 12 of the Constitution of the Company, approval be and is hereby given to waive the pre-emptive rights		7.	All resolutions set out in this Notice will be put to vote by of Bursa Malaysia Securities Berhad ("Bursa Securities").	poll pursuant to Paragrap	oh 8.29A(1) of the Main Ma	rket Listing Requirements
	of the shareholders of the Company to be offered new shares of the Company ranking pari-passu in all respects with the existing ordinary shares arising from any issuance and allotment of shares pursuant to this approval.		C.	AUDITED FINANCIAL STATEMENTS FOR FINANCIAL YE	AR ENDED 31 DECEMBER	R 2023	
	AND THAT the Directors be and are also empowered to obtain the approval from Bursa Malaysia Securities			The audited financial statements are for discussion onl provisions of Section 340(1)(a) of the Act. Hence, this Age	y under Agenda 1, as the enda 1 is not put forward f	ey do not require shareho or voting.	lders' approval under the
	Berhad for the listing of and quotation for the additional shares so issued AND FURTHER THAT such authority shall continue to be in force until the conclusion of the next Annual General Meeting of the Company."	Resolution 7	D.	EXPLANATORY NOTES			
7.	Proposed Renewal of Existing Shareholders' Mandate for Recurrent Related Party Transactions of a Revenue or Trading Nature ("Proposed Renewal of RRPT Mandate")			Resolutions 1, 2 and 3 The Board, on the recommendation of the Nomination	n and Remuneration Con	nmittee ("NRC") sunnorti	ed the re-election of the
	"THAT approval be and is hereby given to the Company and its subsidiaries ("WCT Group") to enter into and give			retiring Directors. The Board and NRC has reviewed the the independence assessment of Independent Directors	e performance of the reti	iring Directors via an ann	ual assessment including
	effect to the recurrent related party transactions of a revenue or trading nature and with all classes of related parties as set out in Section 2, Part A of the Circular to Shareholders dated 26 April 2024 which are necessary for			performance and contribution of the retiring Directors th	at they had effectively dis	charged their duties and re	
	the Group's day-to-day operations, provided that:			Directors also have met the fit and proper criteria as set o The retiring Directors do not hold any shares in the Com			Directors of the Company's
	 the transactions are in the ordinary course of business and are carried out at arm's length basis on normal commercial terms of the WCT Group and on terms not more favourable to the related parties than those 			Annual Report 2023.	. , .		
	generally available to the public or third parties where applicable and not to the detriment of the minority			Resolutions 5 and 6 The proposed Ordinary Resolutions 5 and 6, if passed, will facilitate the payment of Directors' fees and benefits payable/provided to the			
				The proposed Ordinary Resolutions 5 and 6, if passed, will	II facilitate the payment of	f Directors' fees and benefit	ts payable/provided to the
	shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the			The proposed Ordinary Resolutions 5 and 6, it passed, will Directors of the Company and its subsidiaries for the peri held in 2025, in accordance with the payment schedule a:	iod commencing from 14.		
	shareholders of the Company; and			Directors of the Company and its subsidiaries for the peri	iod commencing from 14.	June 2024 until the next A	
	shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and			Directors of the Company and its subsidiaries for the peri	iod commencing from 14 s set out below: The Co	June 2024 until the next A mpany Non-Executive	GM of the Company to be Subsidiary Company
	shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information:			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as	iod commencing from 14 s set out below: The Co Executive Director	June 2024 until the next A mpany Non-Executive Director	GM of the Company to be Subsidiary Company Director
	shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until:			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month)	iod commencing from 14 s set out below: The Co	June 2024 until the next A mpany Non-Executive Director RM7,000	GM of the Company to be Subsidiary Company
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general 			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended)	iod commencing from 14 s set out below: The Co Executive Director	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000	GM of the Company to be Subsidiary Company Director
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or 			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee	iod commencing from 14 s set out below: The Co Executive Director	June 2024 until the next A mpany Non-Executive Director RM7,000	GM of the Company to be Subsidiary Company Director
	shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee	iod commencing from 14 s set out below: The Co Executive Director	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 (RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman)	GM of the Company to be Subsidiary Company Director
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or 			Directors of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended)	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member)	GM of the Company to be Subsidiary Company Director RM1,000 - - - - -
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extension as may be allowed pursuant to 			Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) paya attendance fees and benefit-in-kind such as insurance of	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cot Group's Personal Insuranc	GM of the Company to be Subsidiary Company Director RM1,000 - - - - mpany comprise meeting e & Group Hospitalization
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such madate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. 			Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) paya attendance fees and benefit-in-kind such as insurance otheme, Directors' and Officers' Liability Insurance as well	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - ble/provided to Non-Exec coverage pursuant to the as other claimable expens	June 2024 until the next A mpany Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) Utive Directors of the Cor Group's Personal Insurance se incurred in the course o	GM of the Company to be Subsidiary Company Director RM1,000 - - - - - mpany comprise meeting e & Group Hospitalization f carrying out their duties.
	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parties involved in the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the AC1; or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Phopsoed Renewal OR RPI Mandate." 	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) paya attendance fees and benefit-in-kind such as insurance as Scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's feas dubenefits which a pursuant to Section 230(1) of the Act, do not include s	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cot Group's Personal Insurances ses incurred in the course o of the shareholders of the luments of the Executive	GM of the Company to be Subsidiary Company Director RM1,000 - - - - - mpany comprise meeting & Group Hospitalization f arrying out their duties. Company at the 13 th AGM Directors of the Company
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts is involved in the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Reewal of RAPT Mandate." 	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance as well the abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment.	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Course of the shareholders of the luments of the Executive ritue of and pursuant to th	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company eir contracts of service or
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parties involved in the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate: Proposed Renewal of Share Buy-Back Authority THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be angle, endined, modified on re-encider from time to time), the provisions of the Company's Constitution and 	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e cheme, Directors' ad Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors' of the Company's subsidiary companie	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) and a constant of the Cost Group's Personal Insurances ses incurred in the course o of the shareholders of the luments of the Executive rtue of and pursuant to the made by the Company an	GM of the Company to be Subsidiary Company Director RM1,000 - - - - - - - mpany comprise meeting & Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Company's Onsittution and the Main Market Listing Requirements of Bursa Malayias Securities") and approvals of 	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule a Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance as Scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors to the Directors' and when incurred, if the proposed it is just and equitable for the Directors to be paid the	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) rutive Directors of the Cour Group's Personal Insurances incured in the course o of the shareholders of the luments of the Executive true of and pursuant to the made by the Company and assed at the 13° AGM. The	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting & Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company leir contracts of service or d its subsidiaries monthly Board is of the view that ley have discharged their
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(4) of the ACt); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be annewed, or "the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be emedued, modified or re-encated from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance es Scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arreas and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the responsibilities and rendered their services to the Compan The breakdown of the detailed Director's remuneration	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) INU Directors of the Course of of the shareholders of the fuuments of the Executive rtue of and pursuant to the made by the Company Ann this on such basis, after th ughout the current period.	GM of the Company to be Subsidiary Company Director RM1,000 many comprise meeting e Goroup Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Head is of the view that tey have discharged their disclosed in the Corporate
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCI Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies act, 2, 2016 (her "Act"), rules, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Gunpany's Constitution and the Main Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") and approvals of any other relevant authority, the Company be and is hereby authorised, to the fullest extent permitted by law, to pur	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) paya attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) paya attendance fees and benefit-in-kind such as insurance e scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the Company and the Girectors' and Perferent the formation of the Company and the directors of the Company's subsidiary companie employment.	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) INU Directors of the Course of of the shareholders of the fuuments of the Executive rtue of and pursuant to the made by the Company Ann this on such basis, after th ughout the current period.	GM of the Company to be Subsidiary Company Director RM1,000 many comprise meeting e Goroup Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Head is of the view that tey have discharged their disclosed in the Corporate
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal ARPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, requilations and orders made pursuant to the Act (as may be ameded, modified or re-encider fform time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malaysia Securities sorts of the Company be and is hereby authorised, to the fullest extent permitted by law, to purchase such amount of	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e Scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arreas and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the responsibilities and rendered their services to the Company fue Company and Bursa Securities. Resolution 7	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Member) RM2,000 (Member) RM2,000 (Member) the Directors of the Course of the shareholders of the furments of the Executive rtue of and pursuant to the saced at the 13° AGM. The fits on such basis, after th ughout the current period. del 31 December 2023 is a the CG Report, which are a	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting & Group Hospitalization f carrying out thei duties. Company at the 13 th AGM Directors of the Company leir contracts of service or d its subsidiaries monthly Board is of the view that hey have discharged their disclosed in the Corporate vailable at the website of
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conduction of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Company shall on the Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act", rules, regulations and orders made pursuant to the Act (as may be aremeded, modified or re-enacted from time to time), the provisions of the Company's Onstitution and the Main Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") and approvals of any other relevant authority, the Company provided that: (i) the aggregate number of Shares Wuich Marke Securities upon such terms and conditions as the Dir	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e cheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors' of the Ompany's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors the Company State Ompany and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares of	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - ble/provided to Non-Exec coverage pursuant to the as other claimable expens re subject to the approval alaries, benefits and emo of the Company will be 1 Resolutions 5 and 6 are p. Directors' fees and bene to the financial year end Annual Report 2023 and npower the Directors to	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 (RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Con Group's Personal Insurance incurred in the course of of the shareholders of the luments of the Executive es incurred in the course of of the shareholders of the luments of the Executive asced at the 13° AGM. The fits on such basis, after the updout the current period. led 31 December 2023 is of the CG Report, which are ca- allot shares in the Compa ime being, for any possib	GM of the Company to be Subsidiary Company Director RM1,000 npany comprise meeting & Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company leir contracts of service or d its subsidiaries monthly Board is of the view that hey have discharged their disclosed in the Corporate vailable at the website of Iny up to an amount not le fund raising activities,
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be armended, modified or re-enacted from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayais Securities: 9 and approvals of approvals of approvals of the Company be and is hereby authorised, to the fullest extent permitted by law, to purchase such amount of ordinary	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' tability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Sections' of the Ket, do not include s and the directors' of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors' remuneration Governance ("CG") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares c including but not limited to placement of shares, for the and/or so forth. This approval is a renewal of general 1	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - ble/provided to Non-Exec coverage pursuant to the a other claimable expen- ire subject to the approval alaries, benefits and emo s which they receive by vi of the Company will be a Resolutions 5 and 6 are p. Directors' fees and bene Resolutions 5 and 6 are p. Directors' fees and bene for the financial year end is Annual Report 2023 and mpower the Directors to . of the Company for the ti purposes of funding fut sought to the sought to the company for the ti purposes of funding fut sought to Sought to	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 (RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cor Group's Personal Insurano sei ncurrel in the course o of the shareholders of the luments of the Executive of the shareholders of the luments of the Executive assed at the 13 th AGM. The fits on such basis, after th the G Report, which are a allot shares in the Company me being, for any possib are investment projects, we have being, for any possib are investment projects, we	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting & Group Hospitalization f arrying out their duties. Company at the 13 th AGM Directors of the Company eir contracts of service or d its subsidiaries monthly Board is of the view that ley have discharged their disclosed in the Corporate available at the website of Inturn arising activities, orking capital, acquisition i di any delay and cost in
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conduction of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including geneturing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act", rules, regulations and orders made pursuant to the Act (as may be arguered) to give affect and the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Berhad ("Bursa Securities") and approvals of any other relevant authority, the Company provided that: (i) the aggregate number of Shares Wuich May be purchased by the Company shall not exceed ten percent (10%) of the total number of issued ordinary shar	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance « Scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s- and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arreas and/or as and when incurred, if the proposed it is just and equitable for the Directors remuneration Governance ("CG") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares of including but not limited to placement of shares, for the and's of softh. This approval is a renewal of general r	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM2,000 (Member) INUP Directors of the Course of the shareholders of the furue Directors of the Course of the shareholders of the fits on such basis, after th ughout the current period. del 31 December 2023 is the CG Report, which are a allot shares in the Company an re investment projects, w provide flexibility and a provided rav arguestant	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting & Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Board is of the view that tey have discharged their disclosed in the Corporate vailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Company Sonstitution and the Main Market Listing Requirements of Bursa Malayia Securities Plass Automist of the Company from time to time through Bursa Securities of and optermaps for stitution of the caves of the Company form time to time to t	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors' of the Ormany's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arears and/or as and when incurred, if the proposed it is just and equitable for the Directors the Company Employment. Payment of Directors' statement of the Companys the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resoluton 7, if passed, will en exceeding 10% of the total number of issued shares, for the and/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of shares, for andate granted to the Directors at the last AGM of the Company, As at mandate granted to the Directors at the last AGM of the Company.	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - ble/provided to Non-Exec coverage pursuant to the as other claimable expensi- re subject to the approval alaries, benefits and emo s which they receive by vi of the Company will be 1 Resolutions 5 and 6 are p. Directors' fees and bener for the financial year end Annual Report 2023 and power the Directors to : of the Company for the ti purposes of funding fut the purposes of funding fut the sunght to the subgits of the to purpose of funding fut s to-date, no new ordinary company held on 15 June 2	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cor Group's Personal Insurano sei ncurrel in the course o of the shareholders of the luments of the Executive of and pursuant to th made by the Company an assed at the 13° AGM. The fits on such basis, after th updout the current period. led 31 December 2023 is of the CG Report, which are a allot shares in the Compa revoked or varied at a ge 'shares in the Company we 023.	GM of the Company to be Subsidiary Company Director RM1,000 npany comprise meeting e Group Hospitalization farying out their duties. Company at the 13 th AGM Directors of the Company eir contracts of service or d its subsidiaries monthly Board is of the view that hey have discharged their disclosed in the Corporate vailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition orking capital, acquisition orking vail cost, in heral meeting, will expire ere issued pursuant to the
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conduction of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including genecuting such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act", rules, regulations and orders made pursuant to the Act (as may be arguered) to give affect and ("Bursa Securities") and approvals of any other relevant authority, the Company provided that: (i) the aggregate number of Shares Wuich May be guired) to the Company shall not exceed ten percent (10%) of the total number of issued ordinary shares in the Company for the tures and conditions as the Directors of the Gompany parks are the Company provid	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares of indufor so forth. This approval is a renewal of general r convening a general meeting for such allotment of shares in at the conclusion of the next AGM of the Company. As at mandate granted to the Directors at as laos seeking the 5 to allow the Directors and the astrawise the starkes for the Directors of the Company. As at mandate granted to the Directors at heast AGM of the Company. As at mandate granted to the Directors at heast show the Section of the services to allow the Directors at shows whith the Directors to allow and size new weak shows whith the Directors to allow the Directors at the services to allow th	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cor Group's Personal Insurance ses incurred in the course of the shareholders of the luments of the Executive ritue of and pursuant to at made by the Company am sade at the 13° AGM. The fits on such basis, after th ughout the current period. Bit Shares in the Company ime being, for any possib the CG Report, which are a allot shares in the Company provide flexibility and a evoked or variopicst, w provide flexibility and a evoked or variopics the shares in the Company wa 2023.	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization farrying out their duties. Company at the 13 th AGM Directors of the Company eir contracts of service or d its subsidiaries monthly elsoard is of the view that tey have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire re issued pursuant to the Section 85 of the Act and
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Company Sonstitution and the Main Market Listing Requirements of Bursa Malayia Securities Plass Automist of the Company from time to time through Bursa Securities of and optermaps for stitution of the caves of the Company form time to time to t	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Director's benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance as Scheme, Directors' and Officers' Liability Insurance as well the abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arreas and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the responsibilities and rendered their services to the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares oc including but not limited to placement of shares, for th and'to so forth. This approval is a renewal of general r enversion of the detailed for the Company. Sa ta mandate granted to the Directors at the last AGM of the C The proposed Ordinary Resolution 7 is also seeking the si	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cor Group's Personal Insurance ses incurred in the course of the shareholders of the luments of the Executive ritue of and pursuant to at made by the Company am sade at the 13° AGM. The fits on such basis, after th ughout the current period. Bit Shares in the Company ime being, for any possib the CG Report, which are a allot shares in the Company provide flexibility and a evoked or variopicst, w provide flexibility and a evoked or variopics the shares in the Company wa 2023.	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization farrying out their duties. Company at the 13 th AGM Directors of the Company eir contracts of service or d its subsidiaries monthly elsoard is of the view that tey have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire re issued pursuant to the Section 85 of the Act and
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be armended, modified or re-enacted from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayais Securities "Dava approvals of approvals of the Company from time to time through Bursa Securities apport and contintors of the Company formatine to the modified	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include 5 and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arears and/or as and when incurred, if the proposed it is just and equitable for the Directors remuneration Governance ("CG") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en advar so forth. This approval is a renewal of general r convening a general meeting for such allotment of shares, for the allow the Directors at he last AGM of the Company. As at mandate granted to the Directors at he last AGM of the COmpany. As at mandate granted to the Directors at he last AGM of the COM The proposed Ordinary Resolution 7 is also seeking the s to allow the Directors at he last AGM of the COM The proposed Ordinary Resolution 7 is also seeking the s to allow the Directors and heaves with pursuant to this general mandate. Resolution 8	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) utive Directors of the Cor Group's Personal Insurano sei ncurred in the course o of the shareholders of the luments of the Executive of the shareholders of the luments of the Executive of the shareholders of the luments of the Executive assed at the 13 th AGM. The fits on such basis, after th the CG Report, which are a allot shares in the Company me being, for any possib are investment projects, we shares in the Company we 2023. ir pre-emptive right under shares to the existing shares nto any of the recurrent reind.	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting & Group Hospitalization f draving out their duties. Company at the 13 th AGM Directors of the Company eiter contracts of service or d its subsidiaries monthly Board is of the view that ley have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition ere issued pursuant to the Section 85 of the Act and reholders of the company lated party transactions of
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts is involved in the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Reewal of RAPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be arequired) to give effect to the funancial starmary be may be almoved, modified or e-enacted from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Phana ("Bursa Securities") and approvals of any othe	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors' to be paid the responsibilities and rendered their services to the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of shares, for this and/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of share the Directors to allot and issue new shares with pursuant to this general mandate. Resolutin 8 The proposed Ordinary Resolution 7 is also seeking the s to allow the Directors to allot and issue new shares with pursuant to this general mandate.	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano is incurred in the course o of the shareholders of the luments of the Executive true of and pursuant to th made by the Company an assed at the 13° AGM. The fits on such basis, after th ughout the current period. led 31 December 2023 is the CG Report, which are a allot shares in the Compa irre investment projects, w provide flexibility and ay revoked or varied at a g shares in the Company w 023. ir pre-emptive right under shares to the existing sha	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization f carving out their duties. Company at the 13 th AGM Directors of the Company etic contracts of service or d its subsidiaries monthly Board is of the view that eey have discharged their disclosed in the Corporate available at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition orking capital, acquisition iof any delay and cost in neral meeting, will expire re issued pursuant to the Section 85 of the Act and reholders of the Company lated party transactions of Y which are necessary for olders of the Company
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related party transactions made; and (b) the names of the related parties involved in the recurrent related party transactions made and their relationship with the WCI Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RRPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayais Securities "Danay be determined by the Directors of the Company from time to time through Bursa Securities" and autorial approvals and continuons at the Directors of the Comp	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance scheme, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include as and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the responsibilities and rendered their services to the Company the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares, or hand/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of shar at the conclusion of the next AGM of the Company. As at at the conclusion of the next AGM of the Company. As at a the and/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of shar at the conclusion of the next AGM of the Company. As at a the and the general meeting the South of the South of the the proposed Ordinary Resolution 7, is also seeking the si to allow the Directors to allot and issue new shares with pursuant to this general mandate. Resolution 8 The proposed Ordinary Resolution 8, if passed, will enablic a revenue or trading nature set out in Part A of the Circul	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano is incurred in the course o of the shareholders of the luments of the Executive true of and pursuant to th made by the Company an assed at the 13° AGM. The fits on such basis, after th ughout the current period. led 31 December 2023 is the CG Report, which are a allot shares in the Compa irre investment projects, w provide flexibility and ay revoked or varied at a g shares in the Company w 023. ir pre-emptive right under shares to the existing sha	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization f carving out their duties. Company at the 13 th AGM Directors of the Company etic contracts of service or d its subsidiaries monthly Board is of the view that eey have discharged their disclosed in the Corporate available at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition orking capital, acquisition iof any delay and cost in neral meeting, will expire re issued pursuant to the Section 85 of the Act and reholders of the Company lated party transactions of Y which are necessary for olders of the Company
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Reewal of RAPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be arequired) to give effect to the funancial starm by be merclosed of any other relevant authority, the Company be and is hereby authorised, to the fullest extent permitted by law, to purchase such amount of ordinary shares in the Company for the pursus of the Company's Constitution and the Main Market Listing Requirements of the Company for the pursus of the Company for the tim ebing;	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors' to be paid the responsibilities and rendered their services to the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of shares, for this and/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of share for the Directors to allot and issue new shares with pursuant to this general mandate. Resolution 8 The proposed Ordinary Resolution 7, is also seeking the s to allow the Directors to allot and issue new shares with pursuant to this general mandate. Resolutin8 The proposed Ordinary Resolution 8, if passed, will enabla a revenue or trading nature set out in Part A of the Circul the Group's day-to-day operations. This authority, unleas a general meeting, will expire at the conclusion of the ner by law to be held, whichever is the earliest.	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano RM1,000 (Member) rutive Directors of the Cor Group's Personal Insurano is incurred in the course o of the shareholders of the luments of the Executive true of and pursuant to th made by the Company an assed at the 13° AGM. The fits on such basis, after th ughout the current period. led 31 December 2023 is the CG Report, which are a allot shares in the Compa irre investment projects, w provide flexibility and ay revoked or varied at a ge shares in the Company wo 2023. ir pre-emptive right under shares to the existing sha nto any of the recurrent re ompany dated 26 April 200 within which	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e & Group Hospitalization f carving out their duties. Company at the 13 th AGM Directors of the Company eter contracts of service or d its subsidiaries monthly Board is of the view that ey have discharged their disclosed in the Corporate available at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition orking capital, acquisition iod any delay and cost in neral meeting, will expire re issued pursuant to the Section 85 of the Act and reholders of the Company the next AGM is required
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(4) of the ACt); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of Share Buy-Back Authority THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be ameded, modified or re-encider from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Paris and Conditions as the Directors may deem fit and expedient in the interest" and he formary for the time being; (iii) the maximum funds to be allocated by the Company provided that: (i) the augregate number of Shares Which may be purchased by the Company shall not exceed the relating profits of the Company provided that: (ii) the authority conferred by this res	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule at Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e Scheme, Directors' and Officers' Liability Insurance as well the abovementioned Director's fees and benefits to the Directors and the directors of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arreas and/or as and when incurred, if the proposed it is just and equitable for the Directors remuneration Governance ("CG") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares of including but not limited to placement of shares, for the and the directors of laberctors' remuneration Governance ("GC") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will enable at mandate granted to the Directors at the last AGM of the C The proposed Ordinary Resolution 8, if passed, will enable a revenue or trading nature set out in Part A for the Crut the Group's day-to-day operations. This authority, unless a general meeting. Will expire at the condusion of the ne by law to be held, whichever is the earliest. Resolution 9 The proposed Ordinary Resolution 9, if passed, sito approxed in the ast by law to be held, whichever is the earliest.	ide commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) INUE Directors of the Course of the shareholders of the fuuments of the Executive rtue of and pursuant to a sea incurred in the course of of the shareholders of the fits on such basis, after th under by the Company am sade at the 13° AGM. The fits on such basis, after th the GG Report, which are a allot shares in the Company ime being, for any possibility and a revoked or varied at a ge shares in the Company wan v023. In pre-emptive right under shares to the existing shares anto any of the recurrent re of the period within which my to purchase its own shi ulated in the Main Marke	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Board is of the view that tey have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire ree issued pursuant to the Section 85 of the Act and reholders of the company at the next AGM is required ares for up to 10% of the t listing Requirements of
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act, 2016 ("Act") (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of RBPT Mandate." Proposed Renewal of Share Buy-Back Authority "THAT subject to the Companies Act, 2016 (the "Act"), rules, regulations and orders made pursuant to the Act (as may be amended, modified or re-enacted from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Plarsa Securities") and approvals of the Company from time to time through Bursa Securities upon such terms and conditions as the Directors may deem fit and expedient in the interest of the Company for the pursose of purc	Resolution 8		Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e cheme, Director's and Officery' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors' of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arrears and/or as and when incurred, if the proposed it is just and equitable for the Directors to be paid the responsibilities and rendered their services to the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en exceeding 10% of the total number of issued shares, for the alow to birectors at he lark AdM of the C The proposed Ordinary Resolution 7, also seeking the sit to allow the Directors at the lark AdM of the C The proposed Ordinary Resolution 7, also seeking the sit andate granet to the Directors at the lark AdM of the C The proposed Ordinary Resolution 7, also seeking the sit andate and the tailer the services to the Company sit to allow the Directors at the lark AdM of the C The proposed Ordinary Resolution 8, if passed, will enabla a revenue or trading nature set out in Part A of the Circul the Group's day-to-day operations. This authority, unless a general meeting, will expire at the conducion of the me by law to be held, whichever is the earliest. Resolution 9 The proposed Ordinary Resolution 9, if passed, sit o given	iod commencing from 14 . s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) INUE Directors of the Course of the shareholders of the fuuments of the Executive rtue of and pursuant to a sea incurred in the course of of the shareholders of the fits on such basis, after th under by the Company am sade at the 13° AGM. The fits on such basis, after th the GG Report, which are a allot shares in the Company ime being, for any possibility and a revoked or varied at a ge shares in the Company wan v023. In pre-emptive right under shares to the existing shares anto any of the recurrent re of the period within which my to purchase its own shi ulated in the Main Marke	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Board is of the view that tey have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire ree issued pursuant to the Section 85 of the Act and reholders of the company at the next AGM is required ares for up to 10% of the t listing Requirements of
8.	 shareholders of the Company; and (ii) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year based on the following information: (a) the type of the recurrent related parts involved in the recurrent related party transactions made and their relationship with the WCT Group. THAT such approval shall continue to be in force until: (a) the conclusion of the next Annual General Meeting ("AGM") of the Company following the general meeting at which such mandate was passed, at which time it will lapse, unless by a resolution passed at the meeting, the authority is renewed; or (b) the expiration of the period within which the next AGM is required to be held pursuant to Section 340(4) of the ACt); or (c) revoked or varied by resolution passed by the shareholders of the Company in a general meeting; whichever is the earlier. AND THAT the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) to give effect to the transactions contemplated and/or authorised by the Proposed Renewal of Share Buy-Back Authority THAT subject to the Companies Act, 2016 (the "Act"), rule, regulations and orders made pursuant to the Act (as may be ameded, modified or re-encider from time to time), the provisions of the Company's Constitution and the Main Market Listing Requirements of Bursa Malayia Securities Paris and Conditions as the Directors may deem fit and expedient in the interest" and he formary for the time being; (iii) the maximum funds to be allocated by the Company provided that: (i) the augregate number of Shares Which may be purchased by the Company shall not exceed the relating profits of the Company provided that: (ii) the authority conferred by this res	Resolution 8	Ε.	Director's of the Company and its subsidiaries for the per held in 2025, in accordance with the payment schedule as Director's Fee (per month) Board Meeting Attendance Fee (per meeting attended) Board Committee Meeting Attendance Fee (per meeting attended) Special and Other Committee Meeting Attendance Fee (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (per meeting attended) The Directors' benefits (excluding Directors' fees) payal attendance fees and benefit-in-kind such as insurance e (cherm, Directors' and Officers' Liability Insurance as well The abovementioned Director's fees and benefits which a pursuant to Section 230(1) of the Act, do not include s and the directors' of the Company's subsidiary companie employment. Payment of Directors' fees and benefits to the Directors in arears and/or as and when incurred, if the proposed it is just and equitable for the Directors' remuneration Governance ("CG") Overview Statement of the Company's the Company and Bursa Securities. Resolution 7 The proposed Ordinary Resolution 7, if passed, will en add/or so forth. This approval is a renewal of general r convening a general meeting for such allotment of sha at the conclusion of the next AGM of the Company, As at andade granted to the Directors at he last AGM of the CO The proposed Ordinary Resolution 7, is Jass seeking the s allow to be birectors to allot and issue new shares with pursuant to this general mandate. Resolution 9 The proposed Ordinary Resolution 5, if passed, will enabla a revenue or trading nature set out in Part A of the Circu the Group's day-to-day operations. This authority, unless a general meeting, will expire a the conclusion of the net by law to be held, whichever is the earliest. Resolution 9 The proposed Ordinary Resolution 9, if passed, is to giw Gompany's total number of issued shares at any time w Bursa Securities. Please refer to the Statement to Shanet	ide commencing from 14. s set out below: The Co Executive Director RM1,000 - - - - - - - - - - - - -	June 2024 until the next A mpany Non-Executive Director RM7,000 RM1,000 RM1,000 RM2,000 (Chairman) RM1,000 (Member) RM2,000 (Chairman) RM1,000 (Member) INUE Directors of the Cont Group's Personal Insurano ses incurred in the course of of the shareholders of the luments of the Executive rtue of and pursuant to the made by the Company an made by the Company an sased at the 13° AGM. The fits on such basis, after th ughout the current period. del 31 December 2023 is i the CG Report, which are a allot shares in the Company ime being, for any possibility and ar revoked or varient projects, w provide flexibility and ar shares to the existing shall nto any of the recurrent re origonal data (26 April 20 uition passed by the shared of the period within which my to purchase its own shi uitated in the Main Marker roposed Renewal of Share	GM of the Company to be Subsidiary Company Director RM1,000 mpany comprise meeting e Group Hospitalization f carrying out their duties. Company at the 13 th AGM Directors of the Company teir contracts of service or d its subsidiaries monthly Board is of the view that tey have discharged their disclosed in the Corporate wailable at the website of Iny up to an amount not le fund raising activities, orking capital, acquisition oid any delay and cost in neral meeting, will expire ree issued pursuant to the Section 85 of the Act and reholders of the company at the next AGM is required ares for up to 10% of the t listing Requirements of

- Details of individuals who are standing for election as Directors (excluding Directors standing for a re-election) There are no individuals who are standing for election as Directors at the forthcoming 13th AGM of the Company, other than the Directors who are standing for re-election pursuant to Resolutions No. 1, 2 and 3 of the Notice of this meeting.
- Statement relating to general mandate for issue of securities in accordance with Paragraph 6.03(3) of the Main Market Listing Requirements of Bursa Securities Details of the general mandate to issue securities in the Company pursuant to Section 75 and 76 of the Act are set out in Explanatory Note for Resolution 7 of the Notice of this meeting.

F. GENERAL MEETING RECORD OF DEPOSITORS

For the purpose of determining a member's eligibility to attend and vote at the 13th AGM, the Company will obtain a General Meeting Record of Depositors as at 7 June 2024 from Bursa Malaysia Depository Sdn Bhd in accordance with Article 57(3) of the Company's Constitution and Section 34(1) of the Securities Industry (Central Depositories) Act, 1991. Only depositors whose names appear therein shall be entitled to attend in person or appoint proxy to attend and/or vote on their behalf via RPEV facilities, at the 13th AGM of the Company. Company

A copy of the Annual Report 2023, Circular to Shareholders, Notice of 13th AGM, Proxy Form, Administrative Details and Request Form are available for download at this link <u>https://www.wct.com.my/13thAGM/</u>

LOH CHEE MUN (SSM PC No.: 201908002041/MAICSA 7025198) CHONG KIAN FAH (SSM PC No.: 201908003381/MIA 17238) Company Secretaries

Securities and any other relevant autonomes for the time being inforce. AND THAT the Directors of the Company be and are hereby authorised to take all such steps as are necessary or expedient to implement, finalise or to effect the purchase(s) of Shares with full powers to assent to any conditions, modifications, resolutions, variations and/or amendments (if any) as may be imposed by the relevant authorities and to do all such acts and things as the Directors may deem fit and expedient in the best interest of the Company in relation to such purchase(s) of Shares.

To transact any other business of which due notice shall have been given.

By Order of the Board

9

Selangor Darul Ehsan 26 April 2024

Resolution 9